Minimal Residual Disease Market To Witness Rapid Growth In Demand During 2019 - 2029

10/feb/2020 10:59:58 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The minimal residual diseases are leukemic cells that stay in a patient during or after treatment. The ongoing treatment of cancer through chemotherapy or radiotherapy is not every time capable of eliminating all the carcinogenic cells and it may moreover be a cause of malignancy. Minimal residual disease test is useful to confirm the traces of leukemic cells during and after the treatment of cancer.

The different treatments employed throughout the onset can be tested by minimal residual disease confirmatory test to check the efficacy of the different tests and choose the best treatment to eradicate the cancer cells. The recurrence of cancer and cell proliferation can be quantitatively measured by the minimal residual disease test.

US FDA approved first Next-Generation Sequencing based test; clonoSEQ Assay that uses multiplex polymerase chain reaction and NGS to identify and quantify certain gene sequences extracted from bone marrow of patients suffering from acute lymphoblastic leukemia and myeloma.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @

Minimal Residual Disease Market: Drivers and Restraints

The rising number of patients with cancer is expected to be the prime factor for the growth of minimal residual disease market. The awareness among people to confirm the presence of carcinogens is expected to be the one of the surging drivers for the minimal residual disease market.

The patients with ongoing cancer treatment is anticipated to be the most important factor that will grow the minimal residual disease market. The inability of flow cytometry, FISH and polymerase chain reactions to quantify beyond 1 per 100,000 cells is certainly expected to shift the focus of patients towards minimal residual disease market with novel technologies that detect approximately 10 times more for recurrence.

The organ transplants wherein major histocompatibility test is required can be one of the applications where minimal residual disease tests employed for more specificity.

The highly funded oncology testing market is expected to rise the number of technologies and the specificity of each test which will help grow the minimal residual disease market.

Minimal Residual Disease Market: Segmentation

Tentatively, the minimal residual disease market can be segmented on the basis of test technique, detection target, test type, end user and geography.

Based on test technique, the global minimal residual disease market is segmented as:

  • PCR
  • FISH
  • NGS

Based on detection target, the global minimal residual disease market is segmented as:

  • Leukemia
  • Lymphoma
  • Solid Tumors
  • Other

Based on test type, the global minimal residual disease market is segmented as:

  • DNA-based test
  • RNA-based test
  • Immunological test

Based on end user, the global minimal residual disease market is segmented as:

  • Hospitals
  • Laboratory centers
  • Specialty Clinics

Access Full TOC of This Report @

blog comments powered by Disqus è un servizio offerto da Factotum Srl